Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects With Insomnia Disorder
NCT04549168 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects With Insomnia Disorder
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 6, 2020
- Completion date
- March 17, 2023
- Enrollment
- 194 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.